Re-186（Sn）HEDP重复序贯给药作为疼痛性骨转移姑息治疗的安全性和有效性。两名患者的初步病例报告。

Safety and efficacy of repeated sequential administrations of Re-186(Sn)HEDP as palliative therapy for painful skeletal metastases. Initial case reports of two patients.

作者信息

Englaro E E, Schroder L E, Thomas S R, Williams C C, Maxon H R

机构信息

Eugene L. Saenger Radioisotope Laboratory, University of Cincinnati Medical Center, Ohio 45267-0577.

出版信息

Clin Nucl Med. 1992 Jan;17(1):41-4. doi: 10.1097/00003072-199201000-00012.

DOI:10.1097/00003072-199201000-00012

PMID:1371956

Abstract

Single intravenous injections of 30 to 35 mCi (1,110 to 1,295 MBq) of Re-186(Sn)HEDP previously have been shown to result in palliation of painful skeletal metastases from prostate cancer. There are no reports of patients receiving repetitive Re-186(Sn)HEDP therapy. We have followed two such patients who received multiple (five to seven) injections of Re-186(Sn)HEDP at 2-month intervals. Each experienced a sustained decrease in both pain and analgesic intake. The only evident clinical or biochemical toxicity was a mild progressive decline in their total platelet counts.

摘要

先前已表明，单次静脉注射30至35毫居里（1110至1295兆贝可）的铼-186（锡）羟乙二膦酸盐可缓解前列腺癌引起的疼痛性骨转移。目前尚无患者接受重复铼-186（锡）羟乙二膦酸盐治疗的报道。我们跟踪了两名这样的患者，他们每隔2个月接受多次（5至7次）铼-186（锡）羟乙二膦酸盐注射。两人的疼痛和止痛药摄入量均持续下降。唯一明显的临床或生化毒性是其血小板总数轻度进行性下降。